Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib for advanced bone and soft tissue sarcoma
ChiCTR-OIC-17013792Phase 2Recruiting
- Sponsor
- Beijing Jishuitan Hospital
- Start
- Sep 2016
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in bone cancer and soft tissue sarcoma (STS), sponsored by Beijing Jishuitan Hospital. Primary endpoints: Progression-free survival and Disease control rate. Started Sep 2016; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
bone cancersoft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR-OIC-17013792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17013792.